arrow
S

Shinji Ohno

Japanese Foundation for Cancer Research
H指数:62
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Axillary adipose tissue–derived lymphatic endothelial cells exhibit distinct transcriptomic signatures reflecting lymphatic invasion status in breast cancer

腋窝脂肪组织来源的淋巴管内皮细胞表现出反映乳腺癌淋巴管侵犯状态的独特转录组特征。

2026-04-080
OAAI
Postoperative course and safety profile of the suture scaffold technique in breast-conserving surgery: a single-institution observational study

乳腺癌保乳手术中缝合支架技术的术后过程与安全性特征:一项单机构观察性研究

2025-12-290
PRE
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey

ER阳性、HER2阴性原发性乳腺癌的辅助S-1联合内分泌治疗:POTENT试验后的预后调查

2025-10-240
OA
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

6th和7th晚期乳腺癌管理国际共识指南 (ABC指南6和7)

BREAST
IF7.9
2024-08-0122
OAAI
High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands
2024-07-130
OAAI
Long-term outcomes of neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) and docetaxel plus carboplatin plus trastuzumab plus pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
2024-05-202
OAAI
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
2024-05-023
PRE
Clinical significance of urinary microRNA expression in primary breast cancer
2024-05-020
PRE
Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients
2024-01-183
PRE
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
2023-09-070
OAAI